I don’t think they have to ‘re do’ the dosing, my understanding is dose selection is part of the early trial stage, to which they need a green light to move forward. I don’t know much about clinical trials but perhaps a way to derisk the whole study so they don’t go down the wrong path? Maybe one of the medical eggheads can confirm
Where we at?, page-272
-
- There are more pages in this discussion • 344 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
26.0¢ |
Change
0.020(8.33%) |
Mkt cap ! $90.94M | |||
| Open | High | Low | Value | Volume |
| 24.5¢ | 26.0¢ | 24.5¢ | $195.9K | 781.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 38000 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 102892 | 9 |
View Market Depth
| Last trade - 16.10pm 27/06/2024 (20 minute delay) ? |
| PAR (ASX) Chart |